Latest Headlines

Latest Headlines

EU advice on Avandia put off until September

The FDA needs some time to think about Avandia safety--and apparently so do European regulators. This week the European Medicines Agency was expected to entertain recommendations on future use of the

FDA orders halt to enrollment in Avandia trial

The much-debated Avandia safety trial is shutting its doors to new patients. After last week's advisory panel meeting, the FDA has ordered GlaxoSmithKline (NYSE: GSK) to stop enrollment in the TIDE

Takeda paid Avandia panelist who voted to withdraw

Another Avandia panelist has confessed a potential conflict of interest. Dr. Abraham Thomas, who heads up the endocrinology and diabetes division at Detroit's Henry Ford Hospital, says he was a paid

Did Avandia panelist disclose GSK speaking fees?

Yet more proof that disclosure is way better than exposure: One of the Avandia advisory panel members is a paid speaker for GlaxoSmithKline (NYSE: GSK), which makes the diabetes drug. But that

Meta-analysis stands trial with Avandia

The FDA's recent Avandia re-evaluation provides a "useful lesson in the complexities and uncertainties of modern medicine," says the Wall Street Journal. It's really statistical techniques and the

India suspends TIDE as Takeda touts Actos

It's Day 2 after the Avandia vote, and the fallout continues. The FDA advisory panel voted Wednesday on the GlaxoSmithKline (NYSE: GSK)drug's safety, and while 12 members voted to withdraw it, more

What is the meaning of the Avandia vote?

After two days of deliberation, we saw a mixed vote on Avandia. Twelve members voted to take off the market, while 17 recommended changing the label to various degrees. Three voted that the drug

12 panel members recommend Avandia withdrawal

The votes are in, and it isn't good news for GlaxoSmithKline's (NYSE: GSK) Avandia (rosiglitazone). Twelve members of an FDA panel voted to recommend market withdrawal; 10 others voted for continued

If Avandia falls, which diabetes meds fill the gap?

We won't have an indication of Avandia 's future until this afternoon's advisory panel vote. And we won't know for sure until FDA itself makes its decision. But analysts tend to think that if Avandia

GSK settles bulk of Avandia suits for $460M

As GlaxoSmithKline (NYSE: GSK) defended Avandia before an FDA advisory panel yesterday, its lawyers were making sure that defense doesn't move to a courtroom--in some 10,000 lawsuits, that is. The